Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
2.
Science ; 377(6603): eabq1841, 2022 07 15.
Artigo em Inglês | MEDLINE | ID: mdl-35699621

RESUMO

The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection against severe disease, often attributed to primed cellular immunity. We investigated T and B cell immunity against B.1.1.529 in triple BioNTech BNT162b2 messenger RNA-vaccinated health care workers (HCWs) with different SARS-CoV-2 infection histories. B and T cell immunity against previous variants of concern was enhanced in triple-vaccinated individuals, but the magnitude of T and B cell responses against B.1.1.529 spike protein was reduced. Immune imprinting by infection with the earlier B.1.1.7 (Alpha) variant resulted in less durable binding antibody against B.1.1.529. Previously infection-naïve HCWs who became infected during the B.1.1.529 wave showed enhanced immunity against earlier variants but reduced nAb potency and T cell responses against B.1.1.529 itself. Previous Wuhan Hu-1 infection abrogated T cell recognition and any enhanced cross-reactive neutralizing immunity on infection with B.1.1.529.


Assuntos
Linfócitos B , Vacina BNT162 , COVID-19 , Imunização Secundária , SARS-CoV-2 , Linfócitos T , Animais , Anticorpos Neutralizantes/imunologia , Anticorpos Antivirais/imunologia , Linfócitos B/imunologia , Vacina BNT162/imunologia , Vacina BNT162/uso terapêutico , COVID-19/imunologia , COVID-19/prevenção & controle , Reações Cruzadas , Humanos , Camundongos , SARS-CoV-2/genética , SARS-CoV-2/imunologia , Glicoproteína da Espícula de Coronavírus/genética , Glicoproteína da Espícula de Coronavírus/imunologia , Linfócitos T/imunologia
3.
Nat Commun ; 13(1): 1379, 2022 03 16.
Artigo em Inglês | MEDLINE | ID: mdl-35296643

RESUMO

Anti tumour necrosis factor (anti-TNF) drugs increase the risk of serious respiratory infection and impair protective immunity following pneumococcal and influenza vaccination. Here we report SARS-CoV-2 vaccine-induced immune responses and breakthrough infections in patients with inflammatory bowel disease, who are treated either with the anti-TNF antibody, infliximab, or with vedolizumab targeting a gut-specific anti-integrin that does not impair systemic immunity. Geometric mean [SD] anti-S RBD antibody concentrations are lower and half-lives shorter in patients treated with infliximab than vedolizumab, following two doses of BNT162b2 (566.7 U/mL [6.2] vs 4555.3 U/mL [5.4], p <0.0001; 26.8 days [95% CI 26.2 - 27.5] vs 47.6 days [45.5 - 49.8], p <0.0001); similar results are also observed with ChAdOx1 nCoV-19 vaccination (184.7 U/mL [5.0] vs 784.0 U/mL [3.5], p <0.0001; 35.9 days [34.9 - 36.8] vs 58.0 days [55.0 - 61.3], p value < 0.0001). One fifth of patients fail to mount a T cell response in both treatment groups. Breakthrough SARS-CoV-2 infections are more frequent (5.8% (201/3441) vs 3.9% (66/1682), p = 0.0039) in patients treated with infliximab than vedolizumab, and the risk of breakthrough SARS-CoV-2 infection is predicted by peak anti-S RBD antibody concentration after two vaccine doses. Irrespective of the treatments, higher, more sustained antibody levels are observed in patients with a history of SARS-CoV-2 infection prior to vaccination. Our results thus suggest that adapted vaccination schedules may be required to induce immunity in at-risk, anti-TNF-treated patients.


Assuntos
COVID-19 , Doenças Inflamatórias Intestinais , Vacinas Virais , Anticorpos Monoclonais Humanizados/uso terapêutico , Vacina BNT162 , Vacinas contra COVID-19 , ChAdOx1 nCoV-19 , Humanos , Doenças Inflamatórias Intestinais/tratamento farmacológico , Infliximab/uso terapêutico , SARS-CoV-2 , Linfócitos T , Inibidores do Fator de Necrose Tumoral
4.
Immunology ; 166(1): 68-77, 2022 05.
Artigo em Inglês | MEDLINE | ID: mdl-35156709

RESUMO

SARS-CoV-2 infection results in different outcomes ranging from asymptomatic infection to mild or severe disease and death. Reasons for this diversity of outcome include differences in challenge dose, age, gender, comorbidity and host genomic variation. Human leukocyte antigen (HLA) polymorphisms may influence immune response and disease outcome. We investigated the association of HLAII alleles with case definition symptomatic COVID-19, virus-specific antibody and T-cell immunity. A total of 1364 UK healthcare workers (HCWs) were recruited during the first UK SARS-CoV-2 wave and analysed longitudinally, encompassing regular PCR screening for infection, symptom reporting, imputation of HLAII genotype and analysis for antibody and T-cell responses to nucleoprotein (N) and spike (S). Of 272 (20%) HCW who seroconverted, the presence of HLA-DRB1*13:02 was associated with a 6·7-fold increased risk of case definition symptomatic COVID-19. In terms of immune responsiveness, HLA-DRB1*15:02 was associated with lower nucleocapsid T-cell responses. There was no association between DRB1 alleles and anti-spike antibody titres after two COVID vaccine doses. However, HLA DRB1*15:01 was associated with increased spike T-cell responses following both first and second dose vaccination. Trial registration: NCT04318314 and ISRCTN15677965.


Assuntos
COVID-19 , Anticorpos Antivirais , COVID-19/genética , Vacinas contra COVID-19 , Cadeias HLA-DRB1/genética , Antígenos de Histocompatibilidade Classe I/genética , Humanos , SARS-CoV-2
5.
Science ; 375(6577): 183-192, 2022 Jan 14.
Artigo em Inglês | MEDLINE | ID: mdl-34855510

RESUMO

The impact of the initial severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infecting strain on downstream immunity to heterologous variants of concern (VOCs) is unknown. Studying a longitudinal healthcare worker cohort, we found that after three antigen exposures (infection plus two vaccine doses), S1 antibody, memory B cells, and heterologous neutralization of B.1.351, P.1, and B.1.617.2 plateaued, whereas B.1.1.7 neutralization and spike T cell responses increased. Serology using the Wuhan Hu-1 spike receptor binding domain poorly predicted neutralizing immunity against VOCs. Neutralization potency against VOCs changed with heterologous virus encounter and number of antigen exposures. Neutralization potency fell differentially depending on targeted VOCs over the 5 months from the second vaccine dose. Heterologous combinations of spike encountered during infection and vaccination shape subsequent cross-protection against VOC, with implications for future-proof next-generation vaccines.


Assuntos
Vacina BNT162/imunologia , COVID-19/imunologia , COVID-19/virologia , SARS-CoV-2/imunologia , Adulto , Anticorpos Neutralizantes/sangue , Anticorpos Neutralizantes/imunologia , Anticorpos Antivirais/sangue , Anticorpos Antivirais/imunologia , Antígenos Virais/imunologia , Vacina BNT162/administração & dosagem , Vacinas contra COVID-19/imunologia , Proteínas do Nucleocapsídeo de Coronavírus/imunologia , Proteção Cruzada , Feminino , Pessoal de Saúde , Humanos , Estudos Longitudinais , Masculino , Células B de Memória/imunologia , Mutação , Fosfoproteínas/imunologia , Domínios Proteicos , SARS-CoV-2/genética , Glicoproteína da Espícula de Coronavírus/química , Glicoproteína da Espícula de Coronavírus/imunologia , Linfócitos T/imunologia , Vacinação , Potência de Vacina
6.
Toxins (Basel) ; 13(9)2021 08 29.
Artigo em Inglês | MEDLINE | ID: mdl-34564612

RESUMO

American Foulbrood, caused by Paenibacillus larvae, is the most devastating bacterial honey bee brood disease. Finding a treatment against American Foulbrood would be a huge breakthrough in the battle against the disease. Recently, small molecule inhibitors against virulence factors have been suggested as candidates for the development of anti-virulence strategies against bacterial infections. We therefore screened an in-house library of synthetic small molecules and a library of flavonoid natural products, identifying the synthetic compound M3 and two natural, plant-derived small molecules, Acacetin and Baicalein, as putative inhibitors of the recently identified P. larvae toxin Plx2A. All three inhibitors were potent in in vitro enzyme activity assays and two compounds were shown to protect insect cells against Plx2A intoxication. However, when tested in exposure bioassays with honey bee larvae, no effect on mortality could be observed for the synthetic or the plant-derived inhibitors, thus suggesting that the pathogenesis strategies of P. larvae are likely to be too complex to be disarmed in an anti-virulence strategy aimed at a single virulence factor. Our study also underscores the importance of not only testing substances in in vitro or cell culture assays, but also testing the compounds in P. larvae-infected honey bee larvae.


Assuntos
ADP Ribose Transferases/metabolismo , Proteínas de Bactérias/metabolismo , Toxinas Bacterianas/metabolismo , Abelhas/microbiologia , Paenibacillus larvae/patogenicidade , Fatores de Virulência/metabolismo , Virulência/efeitos dos fármacos , Animais , Interações Hospedeiro-Patógeno , Bibliotecas de Moléculas Pequenas
7.
Sci Immunol ; 5(54)2020 12 23.
Artigo em Inglês | MEDLINE | ID: mdl-33361161

RESUMO

Understanding the nature of immunity following mild/asymptomatic infection with SARS-CoV-2 is crucial to controlling the pandemic. We analyzed T cell and neutralizing antibody responses in 136 healthcare workers (HCW) 16-18 weeks after United Kingdom lockdown, 76 of whom had mild/asymptomatic SARS-CoV-2 infection captured by serial sampling. Neutralizing antibodies (nAb) were present in 89% of previously infected HCW. T cell responses tended to be lower following asymptomatic infection than in those reporting case-definition symptoms of COVID-19, while nAb titers were maintained irrespective of symptoms. T cell and antibody responses were sometimes discordant. Eleven percent lacked nAb and had undetectable T cell responses to spike protein but had T cells reactive with other SARS-CoV-2 antigens. Our findings suggest that the majority of individuals with mild or asymptomatic SARS-CoV-2 infection carry nAb complemented by multispecific T cell responses at 16-18 weeks after mild or asymptomatic SARS-CoV-2 infection.


Assuntos
Anticorpos Neutralizantes/imunologia , Infecções Assintomáticas , COVID-19/imunologia , Linfócitos T/imunologia , Anticorpos Neutralizantes/sangue , Anticorpos Antivirais/sangue , Anticorpos Antivirais/imunologia , Estudos de Casos e Controles , Estudos Transversais , Humanos , SARS-CoV-2/imunologia
8.
Appl Environ Microbiol ; 86(12)2020 06 02.
Artigo em Inglês | MEDLINE | ID: mdl-32276975

RESUMO

Pollination provided by managed honey bees as well as by all the wild bee species is a crucial ecosystem service contributing to the conservation of biodiversity and human food security. Therefore, it is not only the health status of honey bees but also the health status of wild bees that concerns us all. In this context, recent field studies suggesting interspecies transmission of the microsporidium parasite Nosema ceranae from honey bees (Apis mellifera) to bumblebees (Bombus spp.) were alarming. On the basis of these studies, N. ceranae was identified as an emerging infectious agent (EIA) of bumblebees, although knowledge of its impact on its new host was still elusive. In order to investigate the infectivity, virulence, and pathogenesis of N. ceranae infections in bumblebees, we performed controlled laboratory exposure bioassays with Bombus terrestris by orally inoculating the bees with infectious N. ceranae spores. We comprehensively analyzed the infection status of the bees via microscopic analysis of squash preparations, PCR-based detection of N. ceranae DNA, histology of Giemsa-stained tissue sections, and species-specific fluorescence in situ hybridization. We did not find any evidence for a true infection of bumblebees by N. ceranae Through a series of experiments, we ruled out the possibility that spore infectivity, spore dosage, incubation time, or age and source of the bumblebees caused these negative results. Instead, our results clearly demonstrate that no infection and production of new spores took place in bumblebees after they ingested N. ceranae spores in our experiments. Thus, our results question the classification of N. ceranae as an emerging infectious agent for bumblebees.IMPORTANCE Emerging infectious diseases (EIDs) pose a major health threat to both humans and animals. EIDs include, for instance, those that have spread into hitherto naive populations. Recently, the honey bee-specific microsporidium Nosema ceranae has been detected by molecular methods in field samples of bumblebees. This detection of N. ceranae DNA in bumblebees led to the assumption that N. ceranae infections represent an EID of bumblebees and resulted in speculations on the role of this pathogen in driving bumblebee declines. In order to address the issue of whether N. ceranae is an emerging infectious agent for bumblebees, we experimentally analyzed host susceptibility and pathogen reproduction in this new host-pathogen interaction. Surprisingly, we did not find any evidence for a true infection of Bombus terrestris by N. ceranae, questioning the classification of N. ceranae infections as EIDs of bumblebees and demonstrating that detection of microsporidian DNA does not equal detection of microsporidian infection.


Assuntos
Abelhas/parasitologia , Interações Hospedeiro-Patógeno , Nosema/fisiologia , Animais , Trato Gastrointestinal/parasitologia , Especificidade da Espécie
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...